Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study
Not yet recruiting
- Conditions
- Atherosclerotic Vascular DiseaseHeterozygous Familial Hypercholesterolemia
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT06958315
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
Recruiting
- Conditions
- Immunoglobulin A Nephropathy
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT06952426
- Locations
- 🇺🇸
Novartis Investigational site, Boston, Massachusetts, United States
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Phase 2
Not yet recruiting
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: GHZ339Drug: Placebo
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 224
- Registration Number
- NCT06947993
Inclisiran Effectiveness in China: a Pragmatic Randomized Trial
Phase 4
Not yet recruiting
- Conditions
- Coronary Heart Disease
- Interventions
- Combination Product: Standard of Care
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1590
- Registration Number
- NCT06941792
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
Phase 3
Not yet recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT06934967
A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT06931691
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2883
- Registration Number
- NCT06930859
A Study to Describe a Group of Spanish Patients With FMF and to Identify Suboptimally Treated Patients With Minimal Disease Activity and Its Impact on Quality of Life
Completed
- Conditions
- Familial Mediterranean Fever
- First Posted Date
- 2025-04-11
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT06923124
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
DFT383 in Pediatric Participants With Nephropathic Cystinosis
Phase 1
Recruiting
- Conditions
- Nephropathic Cystinosis
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT06910813
- Locations
- 🇺🇸
Emory University School of Medicine-Children's Healthcare of Atlanta (recuiting Cohort 0), Atlanta, Georgia, United States
A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT06905327
- Locations
- 🇳🇿
Novartis Investigative Site, Auckland, New Zealand
© Copyright 2025. All Rights Reserved by MedPath